# Incyte Corporation (NASDAQ: INCY), Wilmington, DE – FDA Inspections

Source: https://www.keypedia.com/companies/incyte-corporation/2f3187b3-71fc-4c7d-95bf-d829cc4eceec

> Inspection records and compliance data for Incyte Corporation in Wilmington, Delaware. 11 FDA inspections on record, last inspected September 11, 2026. Publicly traded as NASDAQ: INCY.

---

## Details

- Name: Incyte Corporation
- FEI Number: 3008992769
- Address Line 1: 1801 Augustine Cut Off
- City: Wilmington
- State: Delaware
- Zip Code: 19803
- Country Name: United States
- Address: 1801 Augustine Cut Off, Wilmington, Delaware 19803, United States
- Country: United States

## Stock

- Stock ticker: INCY
- Exchange: NASDAQ
- Share price: $121.70
- Market cap: $24.8B
- Price as of: November 13, 2026

## Related Documents

- FDA Inspection 1337612 - Incyte Corporation - 2026-09-11 — source: FDA, date: September 11, 2026
- FDA Inspection 1333950 - Incyte Corporation - 2026-08-28 — source: FDA, date: August 28, 2026
- FDA Inspection 1272821 - Incyte Corporation - 2025-09-23 — source: FDA, date: September 23, 2025
- FDA Inspection 1272821 - Incyte Corporation - 2025-09-23 — classification: No Action Indicated (NAI), source: FDA, date: September 23, 2025
- FDA Inspection 1194802 - Incyte Corporation - 2022-11-18 — classification: No Action Indicated (NAI), source: FDA, date: November 18, 2022
- [EIR - Incyte Corporation - 2021-11-15](https://www.keypedia.com/records/eir/incyte-corporation/85295354-a4c4-4df8-bd2e-4d824812028a) — source: FDA, date: November 15, 2021
- FDA Inspection 1157927 - Incyte Corporation - 2021-11-15 — classification: No Action Indicated (NAI), source: FDA, date: November 15, 2021
- FDA Inspection 1140901 - Incyte Corporation - 2021-04-16 — classification: Voluntary Action Indicated (VAI), source: FDA, date: April 16, 2021
- FDA Inspection 1118897 - Incyte Corporation - 2020-02-10 — classification: No Action Indicated (NAI), source: FDA, date: February 10, 2020
- FDA Inspection 1073617 - Incyte Corporation - 2018-11-28 — classification: No Action Indicated (NAI), source: FDA, date: November 28, 2018
- [FDA Inspection 980787 - Incyte Corporation - 2016-04-27](https://www.keypedia.com/records/fda_inspections/incyte-corporation/30e71991-8165-49a2-93b8-fece57d93363) — classification: No Action Indicated (NAI), source: FDA, date: April 27, 2016

## Related Companies

- [Medpace Inc](https://www.keypedia.com/companies/medpace-inc/e09bfcb9-1613-4cc0-8434-8913be0f770d)
- [Regeneron Pharmaceuticals Inc](https://www.keypedia.com/companies/regeneron-pharmaceuticals-inc/fbb2cea0-65e4-4da9-9c5f-eea90c33a84f)
- [Sagent Pharmaceuticals](https://www.keypedia.com/companies/sagent-pharmaceuticals/9b7830c1-51dd-4d82-8287-b320eff537fd)
- [SUN PHARMACEUTICAL INDUSTRIES INC](https://www.keypedia.com/companies/sun-pharmaceutical-industries-inc/35896832-2f85-4257-b499-6aa39d1d5f3b)
- [Cody Laboratories, Inc.](https://www.keypedia.com/companies/cody-laboratories-inc/ff687af7-da97-441d-b0cd-7f20af5e87a9)
- [Taro Pharmaceuticals U.S.A., Inc.](https://www.keypedia.com/companies/taro-pharmaceuticals-usa-inc/05da273e-af73-473f-a144-af7c4e2972c9)
- [Ei LLC](https://www.keypedia.com/companies/ei-llc/88b53134-ac99-4eb2-b709-2a80a826ad7d)
- [Eisai, Inc.](https://www.keypedia.com/companies/eisai-inc/081df088-ce18-4702-a2b3-cb4e48ebe3e4)
- [Teva Pharmaceuticals USA, Inc](https://www.keypedia.com/companies/teva-pharmaceuticals-usa-inc/16ce5163-b7e9-4f34-adce-197945dc8b53)
- [Actavis Italy Spa A Socio Unico](https://www.keypedia.com/companies/actavis-italy-spa-a-socio-unico/7c4ac702-d647-4c5d-a853-472db165127e)

## Related Officers

- [recipient](https://www.keypedia.com/people/michael-morrissey/36769d1a-1990-43bb-9836-325824d0d73c)
- [company_representative](https://www.keypedia.com/people/gaafer-el-mallah/46b3a828-77e0-4000-b717-88996b20174e)
